NEW YORK (GenomeWeb News) – A consortium comprising six industry players and academic partners has been created to identify kinases that could serve as drug targets.

The consortium consists of drug discovery firm SARomics Biostructures; medicinal chemistry company Prestwick Chemical; contract service organization ProQinase; the University of Turin in Italy; the Israel Structural Proteomics Center at the Weizmann Institute of Science; and the TechMedIll platform of the University of Strasbourg, France.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.